ylliX - Online Advertising Network
General Market News

New On NASDAQ Deck, Revelation Bio’s COVID-19 Antiviral Shows Encouraging Preclinical Action

New On NASDAQ Deck, Revelation Bio's COVID-19 Antiviral Shows Encouraging Preclinical Action

<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>

Revelation Biosciences Inc (NASDAQ: REVB) says that it observed a significant decrease in viral load with the prophylactic treatment of REVTx-99 in models of COVID-19 infection. What Happened: REVTx-99 was assessed for prophylactic antiviral activity against delta variant infection in three separate cell lines.

...read full article on Benzinga

ylliX - Online Advertising Network